ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 38 for:    Not yet recruiting Studies | psychiatric

Feru-guard for Behavioral Symptoms in Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03451760
Recruitment Status : Not yet recruiting
First Posted : March 2, 2018
Last Update Posted : August 3, 2018
Sponsor:
Collaborator:
Oregon Health and Science University
Information provided by (Responsible Party):
Glovia Co., Ltd.

Brief Summary:
This is designed as a randomized, double-blind, placebo-controlled clinical trial with a 12 week intervention period. Seventy participants with a diagnosis of AD, vascular, and mixed dementia with at least 3 behavioral symptoms present from the Neuropsychiatric Inventory Questionnaires (NPI-Q) will be randomized to the Feru-guard (ferulic acid and Angelica archangelica) or placebo group. Participants will be screened first by a telephone interview or briefly in-clinic and then will be scheduled for an in-clinic screen to establish study eligibility prior to the baseline assessment visit. Clinical and biological outcome measures will occur at baseline and 12 weeks.

Condition or disease Intervention/treatment Phase
Behavioral and Psychiatric Symptoms of Dementia Drug: Feru-guard 100M Other: Feru-guard 100M Placebo Phase 2

Detailed Description:

The participants will be assessed for eligibility using the NPI-Q and must have at least 3 symptoms present, and a score of 25 or lower on the Mini Mental State Exam (MMSE). Participants will also be screened for a previous diagnosis of either Vascular Dementia, Alzheimer's disease, or Mixed Dementia using DSM-5 criteria. The primary outcome measure will be a change in the total score of Neuropsychiatric Inventory Questionnaire (NPI-Q) over 12-weeks. The investigators expect the group receiving Feru-guard will have a greater improvement in total NPI score compared to the placebo group at 12-weeks.

The investigators will also collect data on the effect of Feru-guard supplementation on care-giver burden using the NPI-Q subscale of caregiver distress, Zarit Burden Interview (ZBI) screening version, and quality of life (SF-12) over 12 weeks. The investigators will also collect data on changes in global cognition of participants over 12 weeks using the Montreal Cognitive Assessment (MoCA). The investigators will compare secondary outcomes between Feru-guard and control group.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind, placebo-controlled clinical trial with a 12 week intervention period.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: This is a double-blind, placebo-controlled study. The placebos will be matched to the active supplement in both sensory and physical characteristics. The participants, study investigators, research associates, and study coordinators will have no knowledge of study assignment. Data analysis will be performed blinded to treatment status. The OHSU Research Pharmacy will be responsible for establishing a randomization scheme for newly enrolled participants. Additionally, the Research Pharmacy will ensure blinding of all study medications. The investigators will also evaluate the effectiveness of our blinding by giving study evaluators, participants, study partners, and investigators a short questionnaire asking about knowledge of group assignment. The randomization code will be broken only after data analysis or if there are numerous serious adverse events before the end of the study.
Primary Purpose: Treatment
Official Title: Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia
Estimated Study Start Date : September 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia

Arm Intervention/treatment
Experimental: Feru-guard
Over a 12 week period participants will take two 280 mg hard gel capsules of Feru-guard 100M per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal. Each capsule contains 180.32 mg ferulic acid and 20.02 mg of Angelica archangelica. Total daily dose will be 560mg of Feru-guard 100M, with 360.64 mg of ferulic acid and 40.04 mg of Angelica archangelica.
Drug: Feru-guard 100M
Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.

Placebo Comparator: Placebo
Over a 12 week period participants will take two 280 mg hard gel capsules of a placebo per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal.Total daily dosage will be 560mg of a maltodextrin, calcium stearate, and vanilla food flavor mixture.
Other: Feru-guard 100M Placebo
In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
Other Name: Placebo




Primary Outcome Measures :
  1. Change from Baseline Neuropsychiatric Inventory Questionnaire at 12 weeks [ Time Frame: Administered 2 times 1 baseline, then 12 weeks later. ]
    The NPI-Q is a structured interview with a caregiver or qualified study partner (defined as having direct contact > 2 days/week) that evaluates both presence and severity of 12 neuropsychiatric features which include: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability, lability, apathy, aberrant motor behavior, night-time behavior, and appetite/ eating changes. If the response to the domain question is "No", the informant goes to the next question. If "Yes", the informant then rates both the Severity of the symptoms present within the last month on a 3-point scale ranging from 1 to 3 (mild to severe). Change in overall NPI-Q score between baseline and at 12 weeks will be the primary outcome measure.


Secondary Outcome Measures :
  1. Change from Baseline Neuropsychiatric Inventory Questionnaire subscale of caregiver distress at 12 weeks [ Time Frame: Administered 2 times 1 baseline, then 12 weeks later. ]
    The NPI-Q is a structured interview with a caregiver or qualified study partner (defined as having direct contact > 2 days/week) that evaluates both presence and severity of 12 neuropsychiatric features which include: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability, lability, apathy, aberrant motor behavior, night-time behavior, and appetite/ eating changes. A modification of the original NPI is the addition of a Caregiver Distress Scale for evaluating the psychological impact of neuropsychiatric symptoms reported to be present. For each feature the caregiver distress score ranges from 1-5 (No distress to extreme distress). The caregiver distress subscale score is the sum of the distress scores for each of the 12 features. Change in overall NPI-Q subscale of caregiver distress score which is the between baseline and at 12 weeks will be a secondary outcome measure.

  2. Change from Baseline Zarit Burden Interview Screening Version at 12 weeks [ Time Frame: Administered 2 times 1 baseline, then 12 weeks later. ]
    The Zarit Burden Interview (ZBI) Screening Version is a popular caregiver self-report measure used by many aging agencies, and originated as a 29-item questionnaire. The revised screening version contains 4 items and has been validated. Each item on the interview is a statement which the caregiver is asked to endorse using a 4-point scale. Response options range from 0 (Never) to 4 (Nearly Always). Change in overall ZBI score between baseline and at 12 weeks will be a secondary outcome measure.

  3. Change from Baseline Short Form Health Survey 12-Item at 12 weeks [ Time Frame: Administered 2 times 1 baseline, then 12 weeks later. ]
    The 12-Item Short Form Health Survey (SF-12) is a 12-item validated shortened version of the SF-36 and was designed to provide a health-related quality of life (HRQL) measure that was quick and easy to administer in large population studies. The SF-12 contains a subset of the 12 items from the SF-36 and information from this subset of questions is used to construct a physical and mental component summary score (PCS and MCS, respectively). Change in overall SF-12 score between baseline and at 12 weeks will be a secondary outcome measure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 55 years old or older.
  • Diagnosis of AD, vascular, and mixed dementia
  • Neuropsychiatric Inventory Questionnaire (NPI-Q) at least 3 items out of 12 items are rated as "present."
  • Use of cholinesterase inhibitors, antidepressants and or antipsychotics medications is allowed, if on stable dosage for at least 2 months.
  • Use of memantine and/or serotonin reuptake inhibitors is also allowed, if on stable dose for at least 2 months.
  • Have a committed caregiver who is able and willing to assist them with medications, provide study participant information, and attend all study visits.
  • Sufficient English language skills to complete all testing.
  • MMSE score of 25 or lower.

Exclusion Criteria:

  • Participants who started using antipsychotics or anticholinergics within the previous 2 months.
  • Participants on blood thinners such as warfarin (Coumadin, jantoven), rivaroxaban (xarelto), fondaparinux (arixtra), dibigatran (pradaxa), apixaban (eliquis) dalteparin (fragmin), enoxaparin (lovenox). Aspirin use is allowed.
  • Participants without an identified caregiver.
  • Participants with delirium caused by medicinal poisoning or drug intoxication.
  • Participants who have had the following diseases before the onset of cognitive impairment:

    1. Alcoholism
    2. Manic depression or bipolar disorder
    3. Schizophrenia
  • Participants with malignancy or an acute inflammatory disease.
  • Participants with critical circulatory, respiratory, kidney, or liver disease or diabetes.
  • BMI of >30.
  • Participants who have taken Feru-guard, ferulic acid, or Angelica archangelica supplementation within the last year.
  • Enrollment in another clinical trial or treatment study within the previous 6 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03451760


Contacts
Contact: Jason R David, B.A. 5034949240 dajaso@ohsu.edu

Sponsors and Collaborators
Glovia Co., Ltd.
Oregon Health and Science University
Investigators
Principal Investigator: Lynne Shinto, N.D., M.P.H. Oregon Health and Science University
Principal Investigator: Sarah Goodlin, M.D. Portland VA, Oregon Health and Science University

Publications:
Kar N. Behavioural and Psychological Symptoms of Dementia. In: Kar N, Jolley D, Misra N, editors. Handbook of Dementia. Hyderabad: Paras Medical Publisher; 2005. pp. 54-74.
Sosulski, F., Krygier, K., & Hogge, L. (1982). Free, esterified, and insoluble-bound phenolic acids. 3. Composition of phenolic acids in cereal and potato flours. Journal of Agricultural and Food Chemistry, 30(2), 337-340.
Lempereur, I., Rouau, X., & Abecassis, J. (1997). Arabinoxylan and ferulic acid variation in durum wheat (Triticum durum Desf.) grain and distribution in mill streams. J. Cereal Sci, 25, 103-110.
Jacobson, E. A., Newmark, H., Baptista, J., & Bruce, W. R. (1983). A preliminary investigation of the metabolism of dietary phenolics in humans [Urinary metabolites of caffeic and ferulic acid]. Nutrition Reports International.
Ou, S., & Kwok, K. C. (2004). Ferulic acid: pharmaceutical functions, preparation and applications in foods. Journal of the Science of Food and Agriculture, 84(11), 1261-1269.
Kanaya, K. (2010). Effects of ferulic acid and Angelica archangelica extract (Feruguard) in patients with Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 6(4), S548.
Kimura, T. (2014). A Pilot Study of Tretment with Ferulic Acid and Angelica archangelica Extract for Cognitive Impairment. Journal of New Remedies & Clinics, 63(11), 1848-1855.
National Cancer Institute (NCI). Dietary Screener Questionnaire (DSQ) website:<http://riskfactor.cancer.gov/studies/nhanes/dietscreen/questionnaires.html>. Accessed 6 February 2012.

Responsible Party: Glovia Co., Ltd.
ClinicalTrials.gov Identifier: NCT03451760     History of Changes
Other Study ID Numbers: 17966
First Posted: March 2, 2018    Key Record Dates
Last Update Posted: August 3, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Dementia
Behavioral Symptoms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Ferulic acid
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anticoagulants
Antihypertensive Agents
Cholagogues and Choleretics
Gastrointestinal Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents